Trial Profile
Phase II Trial of Erlotinib Plus Bevacizumab for Patients with Advanced Non-Small-Cell Lung Cancer Who are harboring an EGFR mutation.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2011
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jul 2011 New trial record